medigraphic.com
ISSN 2007-6800 (Print)

2016, Number 2

<< Back Next >>

Rev Mex Traspl 2016; 5 (2)

Exposure to sensitization factors in wait-listed candidates and kidney transplant recipients: behavior during last decade

Guichard-Romero A, Marino-Vázquez LA, Castelán N, López M, González-Tableros N, Arvizu A, De Santiago A, Alberú J, Morales-Buenrostro LE

Language: Spanish
References: 30
Page: 50-56
PDF size: 240.41 Kb.


ABSTRACT

Introduction: Patients with greater exposure to sensitizing factors have a greater risk to develop HLA antibodies that would hinder their ability to have a compatible donor. It has been reported that over time such exposure to sensitizing factors has changed. The aim of this study was to determine the proportion of patients exposed to sensitizing factors, both of the waiting list for a deceased donor, and kidney transplant recipients, as well as the behavior of this exposure through the last decade. Material and methods: An observational, cross-sectional, and descriptive study in patients undergoing kidney transplantation between January/2004 to December/2014, at the National Institute of Medical Sciences and Nutrition «Salvador Zubirán», and patients on the waiting list for a deceased donor on December 2014. The behavior of the proportion of patients with a history of sensitizing factors was analyzed. Results: During the study period 516 kidney transplants were performed, 502 recipients and 51 patients from the waiting list were included. In the transplant population 67.1% had at least a factor of exposure and in patients of the waiting list 88.2%. The number of patients with transfusion before transplantation has remained around 60%. Conclusion: The prevalence of exposure to sensitizing factors in our center remains high and in fact remains almost unchanged in the last decade.


REFERENCES

  1. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant. 2011; 11 (6): 1226-1235.

  2. Kaneku HK, Terasaki PI. Thirty year trend in kidney transplants: UCLA and UNOS renal transplant registry. Clin Transpl. 2006: 1-27.

  3. Sellarés J, de Freitas DG, Mengel M et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012; 12 (2): 388-399.

  4. Hung SY, Lin TM, Chang MY et al. Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients. Hum Immunol. 2014; 75 (6): 531-535.

  5. Bostock IC, Alberú J, Arvizu A et al. Probability of deceased donor kidney transplantation based on %PRA. Transpl Immunol. 2013; 28 (4): 154-158.

  6. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989; 321 (3): 158-163.

  7. Vella JP, O’Neill D, Atkins N, Donohoe JF, Walshe JJ. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant. 1998; 13 (8): 2027-2032.

  8. Sabath E, Vega O, Correa-Rotter R. Referencia temprana al nefrólogo: impacto sobre la hospitalización inicial y los seis primeros meses en diálisis peritoneal continua ambulatoria. Rev Invest Clin. 2003; 55 (5): 489-493.

  9. Roderick P, Jones C, Drey N et al. Late referral for end-stage renal disease: a region-wide survey in the south west of England. Nephrol Dial Transplant. 2002; 17 (7): 1252-1259.

  10. Kessler M, Frimat L, Panescu V, Briançon S. Impact of nephrology referral on early and midterm outcomes in ESRD: EPidémiologie de l’Insuffisance REnale chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective, community-based study. Am J Kidney Dis. 2003; 42 (3): 474-485.

  11. Garcia-Garcia G, Briseño-Rentería G, Luquín-Arellan VH, Gao Z, Gill J, Tonelli M. Survival among patients with kidney failure in Jalisco, Mexico. J Am Soc Nephrol. 2007; 18 (6): 1922-1927.

  12. Laris-González A, Madero-Rovalo M, Pérez-Grovas H, Franco-Guevara M, Obrador-Vera GT. Prevalencia, factores de riesgo y consecuencias de la referencia tardía al nefrólogo. Rev Invest Clin 2011; 63 (1): 31-38.

  13. Marino-Vazquez LA, Sánchez-Ugarte R, Morales-Buenrostro LE. Trasplante renal: primeros mil trasplantes en el Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, en la Ciudad de México. Rev Invest Clin. 2011; 63 (Supl. 1): 6-13.

  14. Mancilla-Urrea E, Aburto-Morales S, Kasep-Bahena J, Rodríguez-Castellanos F. Programa de trasplante renal en el Instituto Nacional de Cardiología Ignacio Chávez. Rev Invest Clin. 2011; 63 (Supl. 1): 14-18.

  15. Gracida-Juárez C, Espinoza-Pérez R, Cancino-López JD et al. Experiencia en trasplante renal en el Hospital de Especialidades Bernardo Sepúlveda del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS). Rev Invest Clin. 2011; 63 (Supl. 1): 19-24.

  16. Arellano-Torres EM, Guerrero-González E, Sánchez-Ramirez H et al. Trasplante renal. Experiencia en el Hospital Universitario José E. González, UANL, en Monterrey, México. Rev Invest Clin. 2011; 63 (Supl. 1): 25-29.

  17. Reyes-Acevedo R, Romo-Franco L, Delgadillo-Castañeda R et al. Programa de trasplante renal del centenario Hospital Miguel Hidalgo en Aguascalientes, México. Rev Invest Clin. 2011; 63 (Supl. 1): 30-37.

  18. González-Audiffred N, Alfaro-Abúndiz FG, Aranda-Verástegui F et al. Experiencia en trasplante renal, de 1999-2011, en el Hospital Central Dr. Ignacio Morones Prieto de San Luis Potosí. Rev Invest Clin. 2011; 63 (Supl. 1): 38-43.

  19. Mondragón-Ramírez GA, Bochicchio-Riccardelli T, Bernal-Flores L et al. Programa de trasplante renal: Instituto Mexicano de Trasplantes. Modelo de sinergia entre hospital privado y fundaciones de asistencia privada. Rev Invest Clin. 2011; 63 (Supl. 1): 44-49.

  20. Martínez-Mier G, Ávila-Pardo S, Méndez-López MT et al. Efecto del índice de masa corporal sobre resultados postrasplante renal. Rev Mex Traspl. 2012; 1 (1): 8-14.

  21. Macdougall IC, Obrador GT. How important is transfusion avoidance in 2013? Nephrol Dial Transplant. 2013; 28 (5): 1092-1099.

  22. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001; 37 (1 Suppl 1): s182-s238.

  23. Van Arendonk KJ, Garonzik Wang JM, Deshpande NA et al. Practice patterns and outcomes in retransplantation among pediatric kidney transplant recipients. Transplantation. 2013; 95 (11): 1360-1368.

  24. Higgins R, Lowe D, Daga S et al. Pregnancy-induced HLA antibodies respond more vigorously after renal transplantation than antibodies induced by prior transplantation. Hum Immunol. 2015; 76 (8): 546-552.

  25. Hernández-Jiménez J, Hernández-Navarrete LS, Rodríguez-Fernández A et al. Experiencia a largo plazo del programa de trasplante renal del Hospital Regional de Veracruz, México. Rev Mex Traspl. 2012; 1 (1): 15-21.

  26. Noyola-Villalobos HF, Espinoza-Mercado F, Jiménez-Chavarría E et al. Terapia de inducción con Basiliximab en trasplante renal. Doce años de experiencia en el Hospital Central Militar. Rev Mex Traspl. 2014; 3 (1): 12-16.

  27. Montgomery RA, Lonze BE, King KE et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011; 365 (4): 318-326.

  28. Higgins R, Lowe D, Hathaway M et al. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation. 2011; 92 (8): 900-906.

  29. Anantharaman P, Schmidt RJ. Sexual function in chronic kidney disease. Adv Chronic Kidney Dis. 2007; 14 (2): 119-125.

  30. Izguerra-Ochoa LE, Renato-Parra M, Morales-Buenrostro LE. Embarazo y trasplante renal. Rev Mex Traspl. 2015; 4 (1): 20-29.




2020     |     www.medigraphic.com